Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Landscape & Forecast – Disease Landscape & Forecast (G7)

The non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL) therapy market is rapidly evolving as novel agents provide alternatives to conventional chemoimmunotherapy regimens. This report focuses on the most common and commercially relevant B-cell NHLs: diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), follicular lymphoma (FL), chronic lymphocytic leukemia (CLL), and small lymphocytic lymphoma (SLL). The CAR T-cell therapies Breyanzi (BMS), Kymriah (Novartis), Tecartus (Gilead), and Yescarta (Gilead) offer curative potential for all disease subtypes. Bispecific T-cell engagers (BiTEs), such as Lunsumio (Roche), Epkinly / Tepkinly (Genmab / AbbVie), and Columvi (Roche), compete with the CAR T-cell therapies and are experiencing uptake in the relapsed / refractory settings. Antibody drug conjugates (ADCs) are carving out a niche in the treatment of DLBCL; three ADCs are available: Polivy (Roche), Zynlonta (ADC Therapeutics), and Adcetris (Pfizer). The noncovalent BTK inhibitor Jaypirca (Eli Lilly) joins the covalent BTK inhibitors Brukinsa (BeiGene), Calquence (AstraZeneca), and Imbruvica (Johnson & Johnson / AbbVie), thus enabling multiple lines of BTK inhibitor therapy for CLL / SLL and MCL. As these drug classes move into earlier lines of therapy, the treatment sequence is changing and fueling substantial growth of the NHL & CLL therapy market.

Questions answered

• How big are the clinically and commercially relevant drug-treatable NHL & CLL populations, and how will drug-treatment rates evolve over 2024-2034?
• What factors are driving growth in the NHL & CLL market, and which drug class will dominate the treatment of these diseases in 2034?
• How will label expansions for CAR T-cell therapies, BiTEs, and BTK inhibitors into earlier lines of treatment impact the NHL & CLL market?
• Which emerging therapies are the most promising for NHL & CLL, and what is their potential uptake during the forecast period?

Content highlights

• Geographies: United States, EU5, Japan.
• Primary research: Country-specific interviews with thought-leading hematologist-oncologists. Survey data collected for this and other Clarivate research.
• Epidemiology: Diagnosed incidence of NHL & CLL by country; drug-treatable and drug-treated cases segmented by disease subtype and line of therapy.
• Forecast: 10-year, annualized, drug-level sales and patient share of key NHL & CLL therapies through 2034, segmented by brands / generics and epidemiological subpopulations
• Drug treatments: Coverage of key current and late-phase emerging therapies.

Product description

Disease Landscape & Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:

• Optimize your long-term disease and development strategy.
• Quantify market potential for your pipeline assets and those of your competitors.
• Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.
• Gauge the commercial outlook and impact of key market events.